Sugi Predict

Sugi Predict / Compounds / SCHEMBL10327706

SCHEMBL10327706

SCHEMBL10327706

CC(C)(C)C(=O)O[C@H]1CC[C@H]2[C@@H]3CCc4cc(O)ccc4[C@H]3CC[C@]12C

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 7/20 0.79
▸ CYP3A4 P08684 6/20 0.79
▸ KMT2A Q03164 6/20 0.79
▸ MEN1 O00255 5/20 0.79
▸ MAPK1 P28482 3/20 0.79
▸ ALOX15 P16050 3/20 0.79
▸ BRCA1 P38398 1/20 0.79
▸ RECQL P46063 1/20 0.79
▸ MAPT P10636 6/20 0.75
▸ TP53 P04637 4/20 0.75
▸ SMN1; SMN2 Q16637 3/20 0.71
▸ HIF1A Q16665 2/20 0.71
▸ ESR1 P03372 5/20 0.70
▸ PGR P06401 2/20 0.70
▸ ADORA3 P0DMS8 2/20 0.70
▸ AR P10275 2/20 0.70
▸ PTGS1 P23219 2/20 0.70
▸ PDE3A Q14432 2/20 0.70
▸ CYP2C19 P33261 2/20 0.70
▸ PDE4A P27815 1/20 0.70

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6862943 0.90 MAPT (0.75) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL147037 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL12072310 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL12186917 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL8643294 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL24103244 0.89 LMNA (0.84) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL13177178 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL8991456 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL7260222 0.89 LMNA (1.00) LMNACYP3A4KMT2AMEN1MAPK1
SCHEMBL9273487 0.88 LMNA (0.82) LMNACYP3A4KMT2AMEN1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF VAN BOGAERT GINA (BE) 2026-01-15 — — US disclosed
CN-118984680-A Tissue manipulation system and method of use thereof 泰利福生命科学有限责任公司 2024-11-19 — — CN disclosed
WO-2023223235-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF PURNA PHARMACEUTICALS NV (BE) 2023-11-23 — — WO disclosed
US-9422241-B2 Demethylpenclomedine analogs and their use as anti-cancer agents DEKK-TEC, INC. (US) 2016-08-23 — — US disclosed
US-20160008376-A1 Compositions, Methods and Uses for Treating Gender-Biased Immune Disorders BIOCOPEA LIMITED (GB) 2016-01-14 — — US disclosed
WO-2016005599-A1 COMPOSITIONS, METHODS AND USES FOR TREATING GENDER-BIASED IMMUNE DISORDERS BIOCOPEA LIMITED (GB) 2016-01-14 — — WO disclosed
US-20120177634-A1 DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS DEKK-TEC, INC. 2012-07-12 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260014080-A1 LIPOSOMAL PREPARATION WITH ENCAPSULATED HORMONES, METHOD OF PRODUCTION AND USE THEREOF NR5A1, SHBG, GNRHR LMNA 796/4885CYP3A4 1458/4885KMT2A 3205/4885
US-20120177634-A1 DEMETHYLPENCLOMEDINE ANALOGS AND THEIR USE AS ANTI-CANCER AGENTS MCL1, DNMT1, MYC LMNA 1636/4885CYP3A4 3548/4885KMT2A 103/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.